ArticleJournal of ophthalmology2012
Adverse effects of systemic immunosuppression in keratolimbal allograft.
Article in Journal of ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Review
- Genetic analysis of allogenic donor cells after successful allo-limbal epithelial transplantation in simple and cultivated limbal epithelial transplantation procedures.Scientific reports · 2023Article
- Outcome of keratolimbal allograft transplantation with deep anterior lamellar keratoplasty for bilateral limbal stem cell deficiency.Frontiers in medicine · 2022Article
- Review
- Clinical Trials of Limbal Stem Cell Deficiency Treated with Oral Mucosal Epithelial Cells.International journal of molecular sciences · 2020Review
- Management Strategies of Ocular Chemical Burns: Current Perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Systemic Immunosuppression for Limbal Allograft and Allogenic Limbal Epithelial Cell Transplantation.Medical hypothesis, discovery & innovation ophthalmology journal · 2020Review
- Strategies for reconstructing the limbal stem cell niche.The ocular surface · 2019Review
- Repairing the corneal epithelium using limbal stem cells or alternative cell-based therapies.Expert opinion on biological therapy · 2018Review
- Emerging Therapeutic Strategies for Limbal Stem Cell Deficiency.Journal of ophthalmology · 2018Review
- Current and Upcoming Therapies for Ocular Surface Chemical Injuries.The ocular surface · 2017Review
- Late Acute Rejection After Allograft Limbal Stem Cell Transplantation: Evidence for Long-Term Donor Survival.Cornea · 2017Observational
- Contact Lens-induced Limbal Stem Cell Deficiency.The ocular surface · 2016Review
- Limbal stem cell transplantation: current perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2016Review
- The ocular surface chemical burns.Journal of ophthalmology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose. Keratolimbal allograft (KLAL) is a treatment for limbal stem cell deficiency. One disadvantage is systemic immunosuppression to avoid rejection. Our purpose was to examine the adverse effects of systemic immunosuppression in KLAL. Methods. A retrospective case review of 16 patients with KLAL who received systemic immunosuppression consisting of a corticosteroid, an antimetabolite, and/or a calcineurin inhibitor was performed. Patients were monitored for signs, symptoms, or laboratory evidence of toxicity. Results. Eleven of 16 patients (68%) experienced an adverse effect. The average age of those with adverse effects was 43.5 years and without was 31.4 years. Ten of 11 patients (91%) had resolution during mean followup of 16.4 months. No serious adverse effects occurred. The most common included anemia, hyperglycemia, elevated creatinine, and elevated liver function tests. Prednisone and tacrolimus were responsible for the most adverse effects. Patients with comorbidities were more likely to experience an adverse effect (82% versus 20%, P = 0.036). Conclusions. KLAL requires prolonged systemic immunosuppression. Our data demonstrated that systemic immunosuppression did not result in serious adverse effects in our population and is relatively safe with monitoring for toxicity. In addition, we demonstrated that adverse effects are more likely in older patients with comorbidities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.